NFL Biosciences includes first smoker in Tonic trial, which is to recruit 310
The first participant in the Tonic trial has been enrolled at the Eurofins Optimed clinical centre in Gières (Isère), NFL Biosciences said in a press release published on 19 November 2026.
This is the first clinical evaluation of NFL-102 in smokers wishing to quit. It follows the receipt of authorisations from the ANSM and the Committee for the Protection of Persons, announced on 22 October.
A trial of 310 smokers, with one dose in three dropped after 40 patients
Tonic is a multicentre, randomised, double-blind, placebo-controlled study that plans to include 310 smokers in France. It is designed to assess the efficacy of NFL-102, a drug candidate designed to strengthen neuroplasticity, which plays a role in addiction.
The primary endpoint is continuous abstinence over four weeks, verified by measuring urinary cotinine. The adaptive protocol makes it possible to select, in stages, the most effective dose from the three initially tested.
Part A, now under way, will involve 40 participants in Gières. At its conclusion, an independent data monitoring committee and the company will review the safety and efficacy data after unblinding, in order to rule out one of the three doses.
Part B then plans for 270 additional participants across about ten centres in France. A further dose selection will take place after the first 150 of them are enrolled, with the following 120 receiving either the selected dose or the placebo for the final evaluation.
NFL-101, second candidate, in preparation for phase 3 and intended for licensing
“This study is central to assessing the potential of our approach,” said Bruno Lafont, chief executive officer of NFL Biosciences. “Our goal is to offer smokers a new option to help them quit tobacco and nicotine and reduce the risk of relapse,” he added.
NFL-102 is the company's second immunotherapeutic approach, alongside NFL-101. The latter, whose efficacy and safety were evaluated in a phase 2 trial, is preparing for phase 3 and is intended to be the subject of a licensing agreement.
Both treatments, derived from tobacco leaves, are designed to be administered as two subcutaneous injections one week apart. When it published its half-year accounts on 22 October 2026, the company reported that its cash runway had been shortened to mid-2027.